Failed Merck cancer candidate lonafarnib shows promise in progeria
This article was originally published in Scrip
Executive Summary
Lonafarnib, an orally bioavailable non-peptidomimetic farnesyl transferase inhibitor (FTI), originally being developed by Schering-Plough as a treatment of solid tumors, may have a future as a treatment for progeria, a rare and fatal rapid-aging disease in children.